ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) — Active Not Recruiting • Phase III • NCT04770753.
- Mitapivat reduced anaemia in patients with non-transfusion-dependent thalassemia compared to placebo.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT). Conditions: Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia Interventions: Placebo Matching Mitapivat, Mitapivat Lead Sponsor: Agios Pharmaceuticals, Inc. Planned Enrollment: 194 participants